Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

5P - Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations


06 Mar 2023


Cocktail & Poster Display session


Jenna Voellinger


Annals of Oncology (2023) 8 (1suppl_2): 100899-100899. 10.1016/esmoop/esmoop100899


J. Voellinger1, C. Passey2, Y.S. Feng3, R. Gunawan1, L. Gibiansky4, D. Polhamus5, A. Gerritsen6, C. O'Day7, L. Nicacio8, I. Soumaoro9, M. Gupta10, W. Hanley11

Author affiliations

  • 1 Quantitative Pharmacology And Disposition, Seagen, Inc., 98021 - Bothell/US
  • 2 Clinical Pharmacology And Quantitative Sciences, Genmab, 08536 - Plainsboro/US
  • 3 Clinical Pharmacology And Quantitative Science, Genmab, 08540 - Princeton/US
  • 4 Pharmacometrics, QuantPharm LLC, 20878 - North Potomac/US
  • 5 Quantitative Sciences, Metrum Research Group, 06081 - Tariffville/US
  • 6 Bioanalytical Sciences, Genmab, 3584CT - Utrecht/NL
  • 7 Translational Sciences, Seagen, Inc., 98021 - Bothell/US
  • 8 Clinical Development, Seagen, Inc., 98033 - Kirkland/US
  • 9 Oncology, Genmab, 08536 - Plainsboro/US
  • 10 Pharmacology, Genmab, 08540 - Princeton/US
  • 11 Quantitative Pharmacology And Disposition, Seagen, Inc., 94080 - San Francisco/US


This content is available to ESMO members and event participants.

Abstract 5P


TV, a tissue factor-directed antibody-drug conjugate, is approved under accelerated approval in the US at a dose of 2.0 mg/kg every 21 days (Q3W) for adult patients (pts) with recurrent or metastatic cervical cancer (r/mCC) who have progressed on or after chemotherapy. Based on TV pharmacokinetics (PK) and exposure-response relationships, we hypothesized that a higher dose intensity and optimized key PK parameters can lead to improvement in efficacy. Here, we report a pharmacometric approach to continuously optimize the TV dosing schedule in non-cervical solid tumors.


TV is being evaluated for pts with advanced solid tumors in 3 schedules: Q3W; Days 1, 8, and 15 of a 28-day cycle (3Q4W); and Days 1 and 15 of a 28-day cycle (Q2W). A population-PK-tumor growth inhibition (PPK-TGI) model was developed using available longitudinal tumor size data from 711 pts, using a wide range of doses and 3 schedules, to determine the effect of TV exposure on tumor dynamics. A Markov model was developed to characterize the occurrence, severity, and duration of ocular adverse events (OAEs). Alternate TV dosing regimen simulations were performed in non-cervical solid tumor populations.


Compared with the approved 2.0 mg/kg Q3W regimen, the PPK model predicted a 26% increase in AUC12wks at 1.2 mg/kg 3Q4W, but DLTs were observed in pts with ovarian cancer. At a lower dose of 0.9 mg/kg 3Q4W, AUC12wks was predicted to decrease 12% and Cmax to decrease 54%; this regimen had a tolerable safety profile but modest antitumor activity. Alternatively, 1.7 mg/kg Q2W predicted a 24% increase in AUC12wks, 15% decrease in Cmax, and a higher Ctrough. PPK-TGI modeling predicted 1.7 mg/kg Q2W to result in more time above the predicted EC50 and a greater reduction in tumor size, thus potentially better efficacy. Markov modeling predicted a potentially higher rate of Grade ≥2 OAEs for 1.7 mg/kg Q2W compared with 2.0 mg/kg Q3W.


TV demonstrated a favorable benefit-risk profile in r/mCC at the approved 2.0 mg/kg Q3W regimen. Along with available data, our modeling approach suggests that a Q2W schedule may lead to improvements in efficacy and potential risk of a higher rate of Grade ≥2 OAEs. Currently, TV is being evaluated at 1.7 mg/kg Q2W in advanced solid tumors in the enrolling innovaTV 207 study.

Clinical trial identification

Editorial acknowledgement

Writing and editorial assistance was provided by Kristoffer Myczek, PhD, and Stephanie Wamsley of Ashfield MedComms, an Inizio Company, and funded by Seagen, Inc.

Legal entity responsible for the study

Seagen, Inc. and Genmab.


Seagen, Inc. and Genmab.


J. Voellinger: Financial Interests, Personal, Full or part-time Employment: Seagen, Inc.; Financial Interests, Personal, Stocks/Shares: Seagen, Inc. C. Passey, Y.S. Feng, A. Gerritsen, I. Soumaoro, M. Gupta: Financial Interests, Personal, Full or part-time Employment: Genmab. R. Gunawan, C. O'Day, L. Nicacio, W. Hanley: Financial Interests, Personal, Full or part-time Employment: Seagen, Inc. L. Gibiansky: Financial Interests, Personal, Full or part-time Employment: QuantPharm Llc; Financial Interests, Personal, Other, Paid Consultant: Seagen, Inc., Genmab. D. Polhamus: Financial Interests, Personal, Full or part-time Employment: Metrum Research Group; Financial Interests, Personal, Other, Paid Consultant: Seagen, Inc., Genmab.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.